Chartered Trade Mark Attorney, Alexandra Nott explores some of the reasons that trade mark protection remains crucial in today’s business environment.
READ MORE
In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.
READ MORE
In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).
READ MORE
The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.
READ MORE
In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.
READ MORE
After more than 20 years, the legislation for Registered Community Designs is being updated. The first phase of these changes will come into force on 1 May 2025.
The Unified Patent Court (UPC) has been open for a little over a year, and its first substantive decisions on revocation and infringement actions are starting to come through. A skim through the UPC decisions page shows that a wide range of groups are getting involved in the UPC, from large to small companies and from engineering to pharma, putting to bed the fear that uptake in this new court would be low.
We look at the general principles of patent working requirements and take a closer look at some jurisdictions which have more stringent requirements on patent working post-grant. We also look at what you can do in order to prevent a third party from accessing your patented technology.
Dehns client, Blackout Technologies, is making headlines with its groundbreaking work in limiting smartphone use in schools. Recently featured in The Times, on BBC Radio 4 and other news outlets, the company is gaining well-deserved recognition for its innovative approach.
Icelandic performance artist Odee Friðriksson’s work, We’re Sorry—an attempt to tackle corporate wrongdoing—has floundered in the High Court. Dehns Trade Mark Attorney, Tiernan Graham, discusses.
In a recent decision, the UPC Court of Appeal ruled on the correction of errors in a patent by interpretation. This case, concerning Alexion Pharmaceuticals’ patent (EP3167888), underscores the importance of precise drafting and consistency in arguments used during patent litigation.
In a trade mark infringement case brought by Shorts International Limited (“SIL”) against Google LLC (“Google”) in the High Court of England and Wales, a decision by Michael Tappin KC towards the end of 2024 gave a salutary reminder regarding the scope of trade marks containing descriptive elements.
As of 1 January 2025 some changes to UK Supplementary Protection Certificate (SPC) practice will come into force in relation to human medicines.
Has a single UPC action yet been stayed in view of a parallel EPO opposition? The court is very reluctant to be delayed by EPO opposition proceedings and remains patentee-friendly in its general approach.
In its long-awaited judgment in SkyKick v Sky, the Supreme Court reversed significant aspects of the Court of Appeal’s decision on bad faith. This landmark ruling reshapes the interpretation of bad faith in UK trade mark law, with wide-ranging implications for the filing, enforcement, and scope of trade marks.
Subscribe here for updates on IP news, events and webinars.
|